

## Appendix C. Study Activities

	Treatment					Follow-Up		Follow-up Phone Call
	V1	V2	V3	V4	V5 (EOT/Early EOT <sup>s</sup> )	V6	EOS (EOT/Early EOT + 16 Weeks)	
<b>Week</b>	<b>0<sup>a</sup></b>	<b>4<sup>t</sup></b>	<b>12</b>	<b>24</b>	<b>36</b>	<b>48</b>	<b>52</b>	<b>56</b>
<b>Day</b>	<b>1</b>	<b>29 ± 4</b>	<b>85 ± 4</b>	<b>169 ± 4</b>	<b>253 ± 4</b>	<b>336 ± 4</b>	<b>365 ± 4</b>	<b>392 ± 4</b>
Informed Consent <sup>b</sup>	X							
Inclusion/exclusion criteria	X							
Medical/Surgical History <sup>c</sup>	X <sup>a</sup>							
Patient's Global Assessment of Disease Activity (VAS) (PtGA) <sup>d</sup>	X <sup>a</sup>	X	X	X	X	X	X	
Patient's Assessment of PsA Pain Intensity (VAS) <sup>d</sup>	X <sup>a</sup>	X	X	X	X	X	X	
HAQ-DI <sup>d</sup>	X <sup>a</sup>	X	X	X	X	X	X	
BASDAI <sup>d,m</sup>	X <sup>a</sup>			X	X	X	X	
SF-36v2 <sup>d</sup>	X <sup>a</sup>	X	X	X	X	X	X	
FACIT-F <sup>d</sup>	X <sup>a</sup>			X	X	X		
Vital Signs <sup>c</sup>	X <sup>a</sup>	X	X	X	X	X	X	
ECG <sup>e</sup>	X <sup>a</sup>			X		X	X	
Physical Exam <sup>e</sup> (c = complete, t = targeted)	X-c <sup>a</sup>	X-t	X-t	X-t	X-t	X-t	X-c	
Concomitant Therapy <sup>f</sup>	X <sup>a</sup>	X	X	X	X	X	X	X